Brind.

Hengrui has formed broad partnerships and licensing deals with Merck & Co., GSK, and Merck KGaA regarding advanced heart disease drugs for hypertrophic cardiomyopathy.

1 report, 1 independent Updated Sep 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA Hengrui GSK

Keep exploring

The entities involved

Merck KGaA
German multinational science and technology company
- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05
Hengrui
Republic of China person CBDB = 91660

Nothing else this week.
GSK
British multinational pharmaceutical and biotechnology company
- Clement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Mon 15:26
- GSK acquired Sierra Oncology.Mon 14:28

Related events

Kailera Therapeutics and Hengrui announced a multi-billion-dollar partnership, while Merck seeks pipeline assets to offset revenue decline.Aug 18

Coverage

Newest first; wire copies grouped

Sep 5BioPharma DiveBravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free da